A study in Arthritis Research & Therapy found that patients with rheumatoid arthritis (RA) experience shoulder pain early in the course of the disease, suggesting that screening of shoulder function should become a larger focus for maintenance and treatment of RA.
The field of rheumatology is largely the same whether it is in the civilian or military world. Differences can be seen in the cause of some of these conditions as well as the treatment options pursued by doctors.
A study in BMC Musculoskeletal Disorders suggests that multinucleated giant cells (MGC) may contribute to osteoarthritis (OA) and rheumatoid arthritis (RA) in addition to their known association with synovitis severity. The finding adds to other recent research and points to the therapeutic potential of targeting MGCs to improve pain and joint damage in both types of arthritis.
Certolizumab pegol (CZP) + methotrexate (MTX) is safe and effective for patients with rheumatoid arthritis (RA) with disease activity despite methotrexate therapy, according to a five-year follow-up study published in Arthritis Research & Therapy. The finding is an extension of the Rheumatoid Arthritis Prevention of Structural Damage (RAPID 2) randomized, controlled trial. It is important because patients with RA are likely to undergo treatment with anti-tumor necrosis factor (anti-TNF) medications over several years.
Functional ability in early rheumatoid arthritis can be improved with intensive initial therapy with triple disease modifying anti-rheumatic disease (DMARD) drugs, according to results of a study presented at the European League Against Rheumatism Annual Congress in Rome, Italy in June.